A novel mutation involving the carboxy terminal region of the FGFR3 gene in a multiple myeloma patient with t(4;14) Leukemia (2002) 16, 1201-1202. DOI: 10.1038/sj/leu/2402502 TO THE EDITOR The t(4;14)(p16.3;q32) chromosomal translocation in MM leads to the apparent deregulation of the fibroblast growth-factor receptor 3 (FGFR3) gene and the novel WHSC1/MMSET gene, whose 5′ untranslated region lies approximately 50 kb centromeric of FGFR3 on 4p16. [1] [2] [3] We have recently demonstrated that this lesion occurs in approximately 20% of MM patients. 4, 5 Interestingly, FGFR3 gene mutations known to be associated with severe forms of dominant human skeletal disorders, such as thanatophoric dysplasia (TD) type I and II, 6 have also been identified in some MM tumors with t(4;14): the Y373C mutation in the KMS-11 cell line, 1,2 the K650E mutation in the OPM-2 cell line, and the K650M mutation in a primary tumor. 1 Using a combination of RT-PCR, SSCP and direct DNA sequencing, we have recently investigated a panel of 11 primary t(4;14) MM tumors overexpressing a deregulated FGFR3 gene, and found only one mutated case (a A248C mutation associated with TDI). 7 The investigation of new patients admitted to our institution has allowed us to identify a case carrying a novel FGFR3 mutation involving the carboxy-terminal region of the gene. The patient (LB2369) was a 65-year-old women who presented at diagnosis a G myeloma in clinical stage IIA; 6 months after diagnosis, she developed plasma cell leukemia and died as a result of the clinical complications. FISH analysis at diagnosis showed the presence of a t(4;14) (p16.3;q32). RT-PCR amplification of the transmembrane domain (TM) demonstrated the overexpression of the FGFR3 and the presence of the IGH-MMSET hybrid transcripts, which were consistent with a breakpoint occurring within intron 3 of the MMSET gene (MB4-2 type). 5 In order to investigate the presence of FGFR3 mutations, we amplified the different domains by means of RT-PCR, and the fragments were further examined using SSCP and direct DNA sequencing as previously reported. 7, 8 RT-PCR amplification of the 193 bp fragment encompassing the FGFR3 stop codon using primers 807F-807R (see legend Figure 1 ) showed that it was shorter in case of LB2369 in comparison with the control; no wild-type fragment was detectable ( Figure 1a ). PCR on tumor DNA showed the presence of both the normal and abnormal fragments (Figure 1a ), thus suggesting that only the mutated allele was expressed in this case. Direct DNA sequencing of the altered RT-PCR fragment showed the presence of an alteration characterized by a T nucleotide (nt) deletion within codon 794 (nt 2420 of FGFR3 cDNA described by Keegan et al 9 ), a GA insertion, and a 46 bp deletion (nt 2427-2472) that started from the third bp of codon 796, encompassed the stop codon (codon 807), and involved 12 nucleotides down stream of it (see Figure 1b) . The FGFR3 transcript therefore has an in-frame sequence that ends at a putative stop codon (nt 2881-2883 in Figure 1b ) located 423 bp from the wild-type stop codon, as confirmed by RT-PCR analysis using a 3′ primer (nt 2902-2920 in Figure 1b ) located down stream of the putative stop codon (data not shown). Overall, these changes may lead to a 932 amino acids long FGFR3 protein containing two amino acid substitutions at codons 794-795, and a carboxy-terminal tail of 136 amino acids from the 3′ untranslated region (see Figure 1b) .
Three distinct missense mutations in the FGFR3 termination codon have been reported in five fetuses affected by TDI. 10 These mutations were expected to produce a FGFR3 protein elongated by 141 amino acids as the mRNA continues through the 3′ untranslated 423 bp up to the same in-frame putative stop codon (nt 2881-2883 in Figure 1b) . It was suggested that this would result in a highly hydrophobic domain with an ␣-helix structure at the carboxy-terminal end of the elongated 11 reported the presence of an inframe deletion of 42 bp encompassing the normal stop codon (codon 807) in the MM5.1 myeloma cell line, which gave rise to a putative protein elongated by 127 amino acids and ending at the same inframe stop codon (Figure 1b) .
11 These authors also demonstrated that this putative protein could induce transformed foci in NIH3T3 cells in vitro, thus suggesting that protein elongation is a strong, albeit unknown mechanism, of FGFR3 activation. Our data further suggest that this mechanism is recurrent within the spectrum of FGFR3 mutations in MM.
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TO THE EDITOR
The incidence of chronic myeloid leukemia (CML) associated with pregnancy is estimated to be 1/75 000. 1 The management of CML during pregnancy poses a therapeutic dilemma because of the potential teratogenic effect of therapy. Several types of treatment have been used for CML during pregnancy included cytotoxic drugs, alpha interferon and leukapheresis. Hydroxyurea (HU) is thought to have the lowest mutagenic potential among the cytotoxic agents. In places like the rural parts of Malaysia where leukapheresis or interferon is not available and termination of pregnancy is unacceptable, the majority of CML patients are managed with HU. Literature review shows that only a few patients treated with HU during pregnancy have been reported. Neither teratogenic nor hematologic consequences to the fetus were detected in these cases. [2] [3] [4] [5] [6] We present a patient with CML in whom HU was used during pregnancy with a successful outcome for both mother and fetus.
A 28-year-old patient was referred at 27 weeks for hyperleuko- /l (65% neutrophils, 10% myelocytes, 4% metamyelocytes, 4% blast, 10% lymphocytes, 1% monocytes and 6% basophils), platelet count (PC) 1340 × 10 9 /l and hemoglobin 10.4 g/dl. Bone marrow examination showed CML in chronic phase. Philadelphia chromosome test was positive. HU, 4 g daily was initiated after obtaining informed consent. Three weeks after receiving HU, the WBC was 8.7 × 10 9 /l and PC, 541 × 10 9 /l. The disease was kept under control with doses of hydroxyurea ranging from 3 to 1.5 g daily. Throughout her pregnancy, ultrasonography showed a normal appearing fetus. Labor was induced at 38 weeks of gestation. The patient's WBC at that time was 17.7 × 10 9 /l. A healthy baby boy weighing 2.68 kg, with Apgar score of 8 at 1 min and 9 at 5 min was delivered vaginally. Clinical examination of the baby showed no abnormality and the blood count was normal. As HU passes into breast milk with the risk of inducing bone marrow suppression, breast-feeding was avoided. The patient and her child continue to do well following delivery. One month postpartum, the patient's blood counts remained stable and alpha interferon therapy was initiated.
The management of CML in pregnancy involves prevention of placental insufficiency and other complications of hyperleukocytosis by control of maternal WBC, while avoiding harmful fetal exposure to cytotoxic drugs. Busulphan and HU inhibit DNA synthesis, and may cause abortion, malformation or fetal growth retardation. Congenital malformations have been observed with busulphan therapy during
